Julia Simões

Dr. Julia Simões

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2022 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
GSGilnei Bruno da Silva
Gilnei Bruno da Silva
DMDaiane Manica
Daiane Manica
ASAlana Patrícia da Silva
Alana Patrícia da Silva
GKGreicy Cristine Kosvoski
Greicy Cristine Kosvoski
MHMarceli Cleunice Hanauer
Marceli Cleunice Hanauer
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI

1 January 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
FAFernanda Dos Anjos
Fernanda Dos Anjos
JSJulia Simões
Julia Simões
CACharles Elias Assmann
Charles Elias Assmann
FCFabiano Carvalho
Fabiano Carvalho
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI
Novel coronavirus disease 2019 (COVID‐19) causes pulmonary and cardiovascular disorders and has become a worldwide emergency. Myocardial injury can be caused by direct or indirect damage, particularly mediated by a cytokine storm, a disordered immune response that can cause myocarditis, abnormal coagulation, arrhythmia, acute coronary syndrome, and myocardial infarction. The present review focuses on the mechanisms of this viral infection, cardiac biomarkers, consequences, and the possible therapeutic role of purinergic and adenosinergic signalling systems. In particular, we focus on the interaction of the extracellular nucleotide adenosine triphosphate (ATP) with its receptors P2X1, P2X4, P2X7, P2Y1, and P2Y2 and of adenosine (Ado) with A2A and A3 receptors, as well as their roles in host immune responses. We suggest that receptors of purinergic signalling could be ideal candidates for pharmacological targeting to protect against myocardial injury caused by a cytokine storm in COVID‐19, in order to reduce systemic inflammatory damage to cells and tissues, preventing the progression of the disease by modulating the immune response and improving patient quality of life.

18 January 2021 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Open access
PDF file
JSJulia Simões
Julia Simões
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI
Declared as a global public health emergency, coronavirus disease 2019 (COVID-19) is presented as a disease of the respiratory tract, although severe cases can affect the entire organism. Several studies have shown neurological symptoms, ranging from dizziness and loss of consciousness to cerebrovascular and neurodegenerative diseases. In this context, Guillain-Barré syndrome, an immune-mediated inflammatory neuropathy, has been closely associated with critical cases of infection with “severe acute respiratory syndrome of coronavirus 2” (SARS-CoV-2), the etiological agent of COVID-19. Its pathophysiology is related to a generalized inflammation that affects the nervous system, but neurotropism was also revealed by the new coronavirus, which may increase the risk of neurological sequel, as well as the mortality of the disease. Thus, considering the comorbidities that SARS-CoV-2 infection can promote, the modulation of purinergic signaling can be applied as a potential therapy. In this perspective, given the role of adenosine triphosphate (ATP) in neural intercommunication, the P2X7 receptor (P2X7R) acts on microglia cells and its inhibition may be able to reduce the inflammatory condition of neurodegenerative diseases. Finally, alternative measures to circumvent the reality of the COVID-19 pandemic need to be considered, given the severity of critical cases and the viral involvement of multiple organs. Graphical Abstract


28 March 2022 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
JSJulia Simões
Julia Simões
AGAgatha Carina Leite Galvan
Agatha Carina Leite Galvan
ESEduarda Luiza Maciel da Silva
Eduarda Luiza Maciel da Silva
ZIZuleide Maria Ignácio
Zuleide Maria Ignácio
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI

22 December 2023 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
GFGabriel Rossi Francisco
Gabriel Rossi Francisco
JSJulia Simões
Julia Simões
GBGeórgia de Carvalho Braga
Geórgia de Carvalho Braga
PGPaulo Henrique Guerra
Paulo Henrique Guerra
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI